JP2012516897A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012516897A5 JP2012516897A5 JP2011549261A JP2011549261A JP2012516897A5 JP 2012516897 A5 JP2012516897 A5 JP 2012516897A5 JP 2011549261 A JP2011549261 A JP 2011549261A JP 2011549261 A JP2011549261 A JP 2011549261A JP 2012516897 A5 JP2012516897 A5 JP 2012516897A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- antibiotic
- composition according
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 38
- 230000003115 biocidal effect Effects 0.000 claims 20
- 230000028327 secretion Effects 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 239000003242 anti bacterial agent Substances 0.000 claims 5
- 208000031729 Bacteremia Diseases 0.000 claims 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 206010034133 Pathogen resistance Diseases 0.000 claims 2
- 208000032536 Pseudomonas Infections Diseases 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 231100000682 maximum tolerated dose Toxicity 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229960000707 tobramycin Drugs 0.000 claims 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 claims 1
- 208000032376 Lung infection Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004100 Oxytetracycline Substances 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 1
- 229960003644 aztreonam Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960002398 demeclocycline Drugs 0.000 claims 1
- -1 eoxycycline Natural products 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 231100000171 higher toxicity Toxicity 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229960004023 minocycline Drugs 0.000 claims 1
- 229960000625 oxytetracycline Drugs 0.000 claims 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims 1
- 235000019366 oxytetracycline Nutrition 0.000 claims 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims 1
- 229960002292 piperacillin Drugs 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 229930101283 tetracycline Natural products 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14995709P | 2009-02-04 | 2009-02-04 | |
| US61/149,957 | 2009-02-04 | ||
| PCT/US2010/023214 WO2010091189A1 (en) | 2009-02-04 | 2010-02-04 | Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012516897A JP2012516897A (ja) | 2012-07-26 |
| JP2012516897A5 true JP2012516897A5 (enExample) | 2013-03-21 |
Family
ID=42133763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549261A Pending JP2012516897A (ja) | 2009-02-04 | 2010-02-04 | シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）感染の治療のための抗生物質と抗体療法との組み合わせ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100272736A1 (enExample) |
| EP (1) | EP2393515A1 (enExample) |
| JP (1) | JP2012516897A (enExample) |
| CA (1) | CA2751433A1 (enExample) |
| WO (1) | WO2010091189A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013515079A (ja) | 2009-12-22 | 2013-05-02 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法 |
| KR102111171B1 (ko) | 2011-06-10 | 2020-05-14 | 메디뮨 엘엘씨 | 항슈도모나스 ｐｓｌ 결합 분자 및 그의 용도 |
| SMT202000542T1 (it) * | 2011-11-07 | 2020-11-10 | Medimmune Ltd | Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas |
| CN114072145B (zh) * | 2020-06-01 | 2024-06-11 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别假单胞菌pcrv的抗体及其用途 |
| FR3114970B1 (fr) | 2020-10-08 | 2023-06-30 | Univ Tours | Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires |
| WO2024261584A1 (en) * | 2023-06-17 | 2024-12-26 | Abgenics Lifesciences Private Limited | A composition effective against beta-lactam antibiotic-resistant pseudomonas aeruginosa |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS63500035A (ja) * | 1985-06-06 | 1988-01-07 | ジエネテイツク システムズ コ−ポレイシヨン | プソイドモナス アエルギノサ 外毒素ａに対する保護用ヒトモノクロ−ナル抗体 |
| NZ218499A (en) * | 1985-12-10 | 1990-04-26 | Genetic Systems Corp | Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods |
| AU615162B2 (en) * | 1986-07-03 | 1991-09-26 | Genetic Systems Corporation | Monoclonal antibodies to pseudomonas aeruginosa flagella |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| AU3580800A (en) | 1998-11-25 | 2000-06-26 | Mcw Research Foundation, Inc. | Method of and compositions for immunization with the (pseudomonas) v antigen |
| JP4355786B2 (ja) * | 2001-01-26 | 2009-11-04 | エムシーダブリユー リサーチ フオンデーシヨン インコーポレーテツド | シュードモナスｖ抗原を用いる免疫化のための方法および組成物 |
| EP1761561B1 (en) | 2004-01-20 | 2015-08-26 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| AU2005306502B2 (en) | 2004-11-16 | 2012-11-15 | Humanigen, Inc. | Immunoglobulin variable region cassette exchange |
| US8211648B2 (en) | 2005-07-22 | 2012-07-03 | Kalobios Pharmaceuticals, Inc. | Secretion of antibodies without signal peptides from bacteria |
| WO2008030988A2 (en) * | 2006-09-06 | 2008-03-13 | The Regents Of The University Of California | Selectively targeted antimicrobial peptides and the use thereof |
| EA201000903A1 (ru) * | 2007-11-30 | 2011-02-28 | Калобиос Фармасьютикалс, Инк. | Антитела к pcrv-антигену pseudomonas aeruginosa |
-
2010
- 2010-02-04 CA CA2751433A patent/CA2751433A1/en not_active Abandoned
- 2010-02-04 US US12/700,599 patent/US20100272736A1/en not_active Abandoned
- 2010-02-04 EP EP10704049A patent/EP2393515A1/en not_active Withdrawn
- 2010-02-04 JP JP2011549261A patent/JP2012516897A/ja active Pending
- 2010-02-04 WO PCT/US2010/023214 patent/WO2010091189A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ali et al. | Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults | |
| Kruis | Antibiotics and probiotics in inflammatory bowel disease | |
| Sanya et al. | Recent advances in therapeutic targets identification and development of treatment strategies towards Pseudomonas aeruginosa infections | |
| Reig et al. | What is new in the anti–Pseudomonas aeruginosa clinical development pipeline since the 2017 WHO alert? | |
| King | Bronchiectasis | |
| ES2983252T3 (es) | Tratamiento de las infecciones polibacterianas | |
| Rhodes et al. | Resistance trends and treatment options in gram-negative ventilator-associated pneumonia | |
| JP2012516897A5 (enExample) | ||
| JP2017519768A5 (enExample) | ||
| JP2013515079A5 (enExample) | ||
| JP2021063090A5 (enExample) | ||
| JP2017512193A5 (enExample) | ||
| JP2017160208A5 (enExample) | ||
| JP2006522830A5 (enExample) | ||
| JP2016507470A5 (enExample) | ||
| JP2019509318A5 (enExample) | ||
| US20220041695A1 (en) | Method for preventing or treating nosocomial pneumonia | |
| JP2015517529A5 (enExample) | ||
| Wróblewska | Novel therapies of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter spp. infections: the state of the art | |
| Sunder et al. | Antibiotics and nano-antibiotics in treatment of lung infection: In management of COVID-19 | |
| JP2012525391A5 (enExample) | ||
| Loos et al. | 674. Pre-Clinical and Phase I Safety Data for Anti-Pseudomonas aeruginosa Human Monoclonal Antibody AR-105 | |
| Dunn | Diagnosis and treatment of infection | |
| Tur | Clinical Microbiology and Infectious Diseases (ECCMID)-28th European Congress. Madrid, Spain-April 21-24, 2018 | |
| Odland | IDWeek 2019 |